Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer
Adult
Science
Carcinoma, Ovarian Epithelial
MicroRNAs/biosynthesis
Neoplasm/biosynthesis
Disease-Free Survival
Databases
Ovarian Neoplasms/genetics
03 medical and health sciences
0302 clinical medicine
80 and over
Humans
RNA, Neoplasm
Aged
Oligonucleotide Array Sequence Analysis
Aged, 80 and over
Ovarian Neoplasms
Nucleic Acid
Gene Expression Profiling
Carcinoma
Q
R
Middle Aged
Ovarian Epithelial/genetics
3. Good health
Survival Rate
Carcinoma, Ovarian Epithelial/genetics
MicroRNAs
RNA
Medicine
Female
Databases, Nucleic Acid
RNA, Neoplasm/biosynthesis
Research Article
DOI:
10.1371/journal.pone.0207319
Publication Date:
2018-11-26T19:39:19Z
AUTHORS (6)
ABSTRACT
Background Ovarian cancer is the leading cause of death by gynecologic cancers in Western world. The aim study was to identify microRNAs (miRNAs) associated with prognosis and/or resistance chemotherapy among patients epithelial ovarian cancer. Methods Using information from Pelvic Mass Study we identified a cohort women Tumor tissues were then collected and analyzed global miRNA microarrays. MiRNA profiling linked survival time progression using Cox proportional-hazards regression models. Logistic models used for analysis chemotherapy. Our results validated external datasets retrieved NCBI Gene Expression Omnibus database. Results A total 197 included microarray analysis. In multivariate analyses number miRNAs significantly correlated overall (miR-1183 (HR: 1.42, 95% CI:1.17–1.74, p = 0.0005), miR-126-3p 1.38, CI:1.11–1.71, 0.0036), (miR-139-3p 1.48, CI: 1.13–1.94, 0.0047), miR-802 0.48, 0.29–0.78, 0.0035)), free (miR-23a-5p (HR:1.32, CI:1.09–1.61, 0.004), miR-23a-3p (HR:1.70, CI:1.15–2.51, 0.0074), 0.29–0.80, 0.0048)), (miR-1234 0.26, 0.11–0.64, 0.003)). few our training cohort, cohorts similar results. Conclusion Eight as significant predictors survival, progression, resistance. these datasets. Inter-platform inter-laboratory variations may have influence on ability compare reproduce use potential markers relapse warrants further investigation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (63)
CITATIONS (32)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....